论文部分内容阅读
目的探讨细辛脑在治疗新生儿感染性肺炎中的临床疗效及安全性。方法将130例新生儿感染性肺炎患儿随机分为治疗组65例,对照组65例,两组均给予常规抗感染和对症治疗,治疗组加用细辛脑注射液0.5 mg/kg次,用5%～10%葡萄糖注射液稀释成0.01%～0.02%的溶液静脉滴注,3～5滴/min,2次/d,疗程为7～10 d。结果治疗组在改善咳嗽、鼻塞、喘憋、气促、啰音消失时间,缩短住院时间,提高治愈率,均高于对照组,且无不良反应发生。两组比较差异有统计学意义(χ2>3.84,P<0.05)。结论细辛脑佐治新生儿感染性肺炎、镇咳、平喘、消除肺部啰音及缩短住院时间,效果满意,且很少有不良反应发生。
Objective To investigate the clinical efficacy and safety of Asarum in the treatment of neonatal pneumonia. Methods Thirty neonates with infectious pneumonia were randomly divided into treatment group (65 cases) and control group (65 cases). Both groups were given routine anti-infective and symptomatic treatment. The treatment group was given Asarone Injection 0.5 mg / kg, 5% ~ 10% glucose injection diluted to 0.01% ~ 0.02% solution of intravenous drip, 3 to 5 drops / min, 2 times / d, treatment for 7 ~ 10 d. Results The treatment group was better than the control group in improving cough, nasal obstruction, wheezing, shortness of breath, rales disappearing time, shortening the hospital stay, and improving the cure rate, and no adverse reactions occurred. The difference between the two groups was statistically significant (χ2> 3.84, P <0.05). Conclusion Asarone treatment of neonatal infectious pneumonia, antitussive, asthma, pulmonary rales and shorten the time to reduce hospitalization, with satisfactory results, and few adverse reactions.